Just under a month ago, WntResearch announced that it had not seen any clinically significant effect of Foxy-5 in the now completed NeoFox study. The work now revolves around securing as much value for the owners as possible. The company’s CEO, Per Norlén, recently provided a market update, and BioStock contacted him to get his thoughts on this.
Read the full article at biostock.se:
https://www.biostock.se/en/2024/10/wntresearch-updates-after-stopped-study/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se